Navigating AL amyloidosis

Episode 7. As the treatment landscape for AL amyloidosis evolves, translating prognostic data into day-to-day clinical decision-making remains a key challenge. Shaji Kumar and Anita D’Souza return to discuss how risk stratification is shaping individualized care across the patient journey. Drawing on emerging evidence and real‑world practice, D’Souza notes that “AL amyloidosis is certainly not a one‑size‑fits‑all disease,” underscoring the importance of personalized, multidisciplinary management.

Diagnostic delays remain a defining challenge in AL amyloidosis, where subtle red flags are often misattributed to far more common conditions. Vaishali Sanchorawala and Shaji Kumar explore the practical steps clinicians can take to recognize AL amyloidosis earlier in the diagnostic journey. Their conversation examines how to heighten clinical suspicion, optimize the use of surrogate biopsy sites, and navigate the increasingly complex landscape of amyloid typing.

As therapeutic innovation accelerates in AL amyloidosis, clinicians are confronted with a rapidly shifting treatment landscape. Taxiarchis Kourelis joins Shaji Kumar to examine how emerging modalities, including cellular therapies, targeted agents, and organ-directed approaches aimed at amyloid clearance, may reshape long held treatment principles. Kourelis reflects on the evolving role of transplant, the promise and pitfalls of immunotherapy-based approaches, and the practical realities of treatment accessibility.

While myeloma is used as a blueprint for treatment of AL amyloidosis, it does not truly reflect its complexity. Dr Anita D’Souza and Dr Kumar discuss the role of clinical trials, the use of autologous stem cell transplant, and how the nature of AL amyloidosis alters response to and side effect profiles of myeloma treatments. Dr D’Souza also offers advice on monitoring treatment response and the steps to take when response is poor.

Dr Anita D’Souza returns to discuss the complex process of identifying and confirming AL amyloidosis. She talks to Dr Kumar about how she uses tests – from blood tests to mass cytometry – in the diagnostic process, why a negative biopsy does not always rule out AL amyloidosis, and why a multidisciplinary approach is critical for good patient outcomes.

AL amyloidosis can present with an astonishing variety of symptoms that masquerade as other diagnoses, making it very easy to miss. Dr Kumar and Dr Anita D’Souza chat about how to recognise when there could be a single underlying cause of accumulating diverse symptoms – and why it’s so important to consider the whole patient to avoid diagnostic delay. Dr D’Souza also talks about strategies for identifying and managing AL amyloidosis coexisting with multiple myeloma.

Linda Perez had 9 years of misdiagnoses before a persistent cardiologist finally realised she had a single underlying disease, by which time she was very ill indeed. She tells Dr Kumar about the huge physical and emotional impact of the disease, the support that patients need from their healthcare team versus what is available, and how different specialists can work together with the patient to successfully manage AL amyloidosis.